Incyte (INCY) Revenue — Quarter Ended Mar 31, 2024
Revenue declined in the first quarter compared with the immediate prior quarter. Despite the sequential drop, revenue was higher than in the same period last year.
Key takeaway
Quarter ended Mar 31, 2024 · FY2024 Q1
Revenue declined in the first quarter compared with the immediate prior quarter. Despite the sequential drop, revenue was higher than in the same period last year.
Financial snapshot
Reported revenue, sequential change, year-over-year change, and trailing four-quarter revenue.
Quarter revenue
$880.9M
Revenue reported for this quarter.
Quarter-over-quarter
-13.1%
Change from the immediately preceding quarter.
Year-over-year
+8.9%
Change from the comparable year-ago quarter.
Trailing four quarters
$3.8B
Sum of the latest four reported quarters.
Quarterly revenue trend
The latest four reported quarters with year-over-year comparisons.
| Period ended | Revenue | Year-over-year change |
|---|---|---|
| Jun 30, 2023 | $954.6M | +4.7% |
| Sep 30, 2023 | $919M | +11.6% |
| Dec 31, 2023 | $1B | +9.3% |
| Mar 31, 2024 | $880.9M | +8.9% |
Revenue performance
Reported revenue decreased from the immediately preceding quarter. The filing context does not provide a cause for the decline, and no causal explanation is offered.
Quarterly comparison
Relative to the prior quarter, revenue was lower. Compared with the same quarter one year earlier, revenue was higher.
What to watch
The filing context references a generic challenge to JAKAFI patents, but no regulatory action is noted to date.